COPD

Latest News


Type 2 Inflammation: A Common Theme Among Several Chronic Diseases

Learn about the multifaceted aspects of type 2 inflammatory diseases, including impact on quality of life; the role of biomarkers in diagnosis and treatment selection; and unmet needs in clinical management.

Type 2 Inflammation: A Common Theme Among Several Chronic Diseases

CME Content


Childhood factors such as asthma, maternal smoking, bronchitis, allergic rhinitis, and eczema predisposed children to lung function decline and chronic obstructive pulmonary disease (COPD) as adults, according to 2 recent studies. Risks might be minimized by reducing maternal smoking, encouraging immunizations, having good asthma control, and avoiding smoking, researchers said.

A study of 2 chronic obstructive pulmonary disease (COPD) inhalers from the same company was published recently in The Lancet Respiratory Medicine. The DYNAGITO trial showed tiotropium bromide and olodaterol, a dual bronchodilator sold under the name Stiolto Respimat, prevented exacerbations better than tiotropium bromide alone (sold as Spiriva Respimat), although not quite as much as expected.

If a health system could identify which patients with chronic obstructive pulmonary disease (COPD) were at risk for exacerbations of disease, interventions aimed at improving health outcomes could be developed. A study to develop and evaluate predictive models that could be used to identify such high-risk patients was unable to do so, however.

Diagnosis-related group coding determines eligibility for many Medicare bundled payment initiatives. This approach excluded many patients with chronic obstructive pulmonary disease likely to benefit while including others without the disease.

Brand Logo

259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo